JGJianguang Gong

Jianguang Gong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jianguang Gong has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Bin Zhu

    Urology & Nephrology Center, Department of Nephrology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China

    2 shared publications
  • Biao Huang

    College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China

    1 shared publication
  • Bo Lin

    Urology & Nephrology Center, Department of Nephrology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China (Xu, Zou, Lin, Zhu, and Gong)

    1 shared publication
  • Chen Lingli

    College of Life Sciences and Medicine Zhejiang Sci‐Tech University Hangzhou China

    1 shared publication
  • He Huang

    Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China

    1 shared publication
  • Jianlan Zheng

    Urology & Nephrology Center, Department of Nephrology, Affiliated People’s Hospital, Zhejiang Provincial People’s Hospital, Hangzhou Medical College, Hangzhou, People’s Republic of China

    1 shared publication

Latest Publications

  • A case of normolipidemic lipoprotein glomerulopathy due to the APOE Kyoto variant

    by Jihao Xu, Wenli Zou, Bo Lin, Bin Zhu, Jianguang Gong

  • Open Access

    Astragaloside IV attenuates uremia-induced myocardial injury by inhibiting autophagy via ATF4

    by Jihao Xu, Qiudi Tu, Li Zhao, Xianyun Ye, Jianlan Zheng, Bin Zhu, Jianguang Gong

    Background Cardiovascular diseases (CVDs) are one of the primary causes of mortality in patients with uremia. The therapeutic value of intravenous Astragaloside (AS-IV) in the treatment of CVDs has been widely recognized. However, whether AS-IV treats CVDs complicated by uremia remains unknown. This study aimed to determine the effects and potential mechanisms of AS-IV in the treatment of CVDs associated with uremia. Methods The 5/6 nephrectomized mouse model and uremic serum (US)-induced myocardial injury model of H9C2 cells were established in this study. Various techniques, including echocardiography, ELISA, TUNEL assay, flow cytometry, Western blotting, immunofluorescence, transmission electron microscopy, and qRT-PCR, were employed to investigate the effects of AS-IV on uremia-associated myocardial injury and determine its impact on autophagy and related signaling pathways. An ATF4 inhibitor and plasmid transfection techniques were used to modulate ATF4 expression and investigate the role of ATF4 in the protective effects of AS-IV on myocardial injury. Results AS-IV significantly improved cardiorenal function and attenuated uremia-associated cardiomyocyte apoptosis in 5/6 nephrectomized mice. Autophagy was significantly activated, and ATF4 expression was increased in 5/6 nephrectomized mice and uremic toxin-treated cardiomyocytes. AS-IV also significantly inhibited ATF4 expression and cardiomyocyte autophagy. Inhibition of ATF4 expression reduced cardiomyocyte apoptosis, while ATF4 overexpression significantly attenuated the cardioprotective effects of AS-IV. AS-IV significantly activated the PI3K pathway, while modulation of ATF4 expression affected AS-IV-mediated activation of the PI3K pathway. Conclusions AS-IV ameliorated uremia-associated myocardial injury by suppressing ATF4 expression and regulating cardiomyocyte autophagy. The PI3K pathway may modulate autophagy after treatment with AS-IV.


  • Open Access

    Establishment of a time‐resolved immunoassay for acute kidney injury based on the detection of Kim‐1

    by Zheng Shaoxiong, Xiumei Zhou, Yuan Qin, Yu Xiaomei, Chen Lingli, Liu Xiaobin, Yigang Wang, Gong Jianguang, Shen Shuijuan, Biao Huang

    Aim: To establish a highly sensitive time‐resolved fluorescence immunoassay (TRFIA) of kidney injury molecule‐1 (Kim‐1) and evaluate its clinical value in acute kidney injury (AKI).Methods: The Kim‐1‐TRFIA was established by the double‐antibody sandwich method, and the method was evaluated. The established Kim‐1‐TRFIA was used to detect the concentration of Kim‐1 in the serum of healthy controls and patients with AKI.Results: The optimal coating antibody concentration and optimal Eu3+‐labeled antibody dilution ratio for Kim‐1‐TRFIA are 1 μg/ml and 1:140, respectively. The linear range is 42.71–4666.69 pg/ml. The intra‐ and inter‐assay coefficients of variation are p < 0.001). Staging patients with AKI by glomerular filtration rate shows that the serum concentration of Kim‐1 increases significantly with increasing disease severity (p < 0.05).Conclusion: A highly sensitive Kim‐1‐TRFIA was established. With this immunoassay, a good differential diagnosis can be made, and healthy people and AKI patients can be differentiated by detecting the concentration of Kim‐1 in the serum. Moreover, the severity of AKI patients can be determined.


  • Top Cited Papers
    Open Access

    Exosome secreted from adipose-derived stem cells attenuates diabetic nephropathy by promoting autophagy flux and inhibiting apoptosis in podocyte

    by Juan Jin, Yifen Shi, Jianguang Gong, Li Zhao, Yiwen Li, Qiang He, He Huang

    It is confirmed that adipose-derived stem cells (ADSCs) transplantation effectively relieves kidney fibrosis and type 2 diabetes disease in mice. Currently, exosome from urine-derived stem cells (USCs) can protect type 1 diabetes-mediated kidney injury and attenuate podocyte damage in diabetic nephropathy (DN). Exosome derived from USCs has evolved into the strategy for DN treatment, but the role of ADSCs-derived exosome (ADSCs-Exo) in DN remains unclear. The present study is aimed to investigate the therapeutic action and molecular mechanism of ADSCs-derived exosome on DN. ADSCs and exosome were authenticated by immunofluorescence and flow cytometry. Morphology and the number of exosome were evaluated by electron microscope and Nanosight Tracking Analysis (NTA), respectively. Cell apoptosis was assessed using flow cytometry. Podocyte autophagy and signaling transduction were measured by immunofluorescence and immunoblotting. Dual Luciferase Reporter assay was employed to detect the regulatory relationship between miR-486 and Smad1. ADSCs-Exo attenuated spontaneous diabetes by reducing levels of urine protein, serum creatinine (Scr), blood urea nitrogen (BUN), and podocyte apoptosis in mice. In in vitro experiment, ADSCs-Exo also reversed high glucose-induced decrease of cell viability and the increase of cell apoptosis in MPC5 cells. In terms of mechanism, ADSCs-Exo could enhance autophagy flux and reduce podocyte injury by inhibiting the activation of mTOR signaling in MPC5 and spontaneous diabetic mice. Eventually, we found that miR-486 was the key factors in ADSCs and in the process of ADSCs-Exo-mediated improvement of DN symptom in vivo and in vitro. miR-486 reduced Smad1 expression by target regulating Smad1 whose reduction could inhibit mTOR activation, leading to the increase of autophagy and the reduction of podocyte apoptosis. In conclusion, we illustrated that ADSCs-Exo vividly ameliorated DN symptom by enhancing the expression of miR-486 which led to the inhibition of Smad1/mTOR signaling pathway in podocyte. Possibly, ADSCs-Exo was used as a main therapeutic strategy for DN in future.